DGX Quest Diagnostics
A steady lab duopolist that compounds slowly; fairly priced unless reimbursement cuts bite hard.
The story
Quest Diagnostics is one half of the US clinical lab duopoly with LabCorp. Its moat comes from scale and density in routine testing, its patient service center network, payer contracts and hospital outreach relationships, which together give it low unit costs. It is a mature, cash-generative business that grows mid-single digits, organically from test volume and advanced diagnostics and through tuck-in acquisitions of hospital outreach labs. Its biggest overhang is reimbursement pressure from PAMA and commercial payers.
Growth of about 5.5% reflects TTM momentum from organic volume plus recent outreach acquisitions, fading to 3.5%, which is near nominal GDP and below the risk-free rate. The margin target of 16.5% is in line with the adjusted (ex-amortization) margins Quest has historically earned, helped by automation and Invigorate cost savings, not a peak. Incremental sales-to-capital of 1.5 sits above the goodwill-heavy historical 0.89 because organic growth needs little capital, though acquisitions remain expensive. The baseline DCF's -53% gap suggests its drivers were too punitive for a stable, heavily covered duopolist.
Value drivers
| Revenue growth (Y1) | 5.5% |
| Terminal growth | 3.5% |
| Forecast horizon | 8y |
| Target operating margin | 16.5% |
| Years to target margin | 5 |
| Sales-to-capital | 1.50 |
| Beta | 0.85 |
| Failure probability | 1.0% |
| Cost of capital (WACC) | 8.4% |
| Terminal WACC | 8.9% |
Valuation bridge
| PV of explicit FCFF | 7.39B |
| PV of terminal value | 13.27B |
| Equity value | 14.86B |
| ÷ shares → per share | $134.62 |
Projected free cash flow to the firm
| Yr | Revenue | Growth | Margin | NOPAT | Reinvest | FCFF | PV |
|---|---|---|---|---|---|---|---|
| 1 | 12.20B | 5.5% | 14.9% | 1.38B | 423.87M | 958.33M | 884.22M |
| 2 | 12.83B | 5.2% | 15.3% | 1.49B | 423.95M | 1.07B | 910.87M |
| 3 | 13.46B | 4.9% | 15.7% | 1.61B | 421.61M | 1.19B | 932.77M |
| 4 | 14.09B | 4.6% | 16.1% | 1.73B | 416.75M | 1.31B | 949.85M |
| 5 | 14.70B | 4.4% | 16.5% | 1.85B | 409.26M | 1.44B | 962.11M |
| 6 | 15.30B | 4.1% | 16.5% | 1.92B | 399.09M | 1.52B | 940.40M |
| 7 | 15.88B | 3.8% | 16.5% | 2.00B | 386.19M | 1.61B | 916.47M |
| 8 | 16.44B | 3.5% | 16.5% | 2.07B | 370.56M | 1.70B | 890.50M |
Key risks
- PAMA Medicare clinical lab fee cuts resuming, along with commercial payer rate pressure
- Overpaying for hospital outreach acquisitions, which erodes returns on capital
- Volume share loss to hospital systems, at-home and point-of-care testing, or Amazon/retail health entrants
Catalysts
- Legislative delay or reform of PAMA cuts (SALSA Act)
- Margin expansion from AI/automation savings and accretive integration of outreach deals